Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer

Expert Review of Anticancer Therapy

Volumn 9, Issue 10, 2009, Pages 1429-1434

  Merseburger, Axel S ^a   Simon, Annika ^a   Waalkes, Sandra ^a   Kuczyk, Markus A ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Metastatic renal cell cancer; Prognosis; Second line; Sequential therapy; Sorafenib; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

AXITINIB; BEVACIZUMAB; CYTOKINE; EVEROLIMUS; LENALIDOMIDE; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; VOLOCIXIMAB;

ALOPECIA; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY FAILURE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PATIENT SELECTION; PROGRESSION FREE SURVIVAL; REVIEW; TUMOR GROWTH;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOLES; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PROGNOSIS; PYRIDINES; PYRROLES;

EID: 70350604479     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.96     Document Type: Review

References (44)

1. Vickers MM, Choueiri TK, Percy A et al. Failure of initial VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC): what next? Presented at: American Society of Clinical Oncology Annual Meeting. Orlando, FL, USA, 29 May-2 June 2009.
2. Bodrogi I. [Effect of angiogenesis inhibitors on renal cell carcinoma]. Magy. Onkol. 51(2), 145-153 (2007).
3. Merseburger AS, Kuczyk MA. [Value of targeted therapies for renal cell cancer]. Urologe A 47(10), 1303-1310 (2008).
4. Kruck S, Merseburger AS, Gakis G, Kramer MW, Stenzl A, Kuczyk MA. An update on the medical therapy of advanced metastatic renal cell carcinoma. Scand. J. Urol. Nephrol. 42(6), 501-506 (2008). • Comprehensive review of medical therapy in renal cell carcinoma (RCC).
5. Bastien L, Culine S, Paule B, Ledbai S, Patard JJ, de la Taille A. Targeted therapies in metastatic renal cancer in 2009. BJU Int. 103(10), 1334-1342 (2009).
6. Mills EJ, Rachlis B, O'Regan C, Thabane L, Perri D. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer 9, 34 (2009).
7. Tamaskar I, Garcia JA, Elson P et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J. Urol. 179(1), 81-86 (2008). (Pubitemid 350216728)
8. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115(1), 61-67 (2009).
9. Eichelberg C, Heuer R, Chun FK et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur. Urol. 54(6), 1373-1378 (2008).
10. Patard JJ, Pouessel D, Culine S. New therapies in renal cell carcinoma. Curr. Opin. Support. Palliat. Care 1(3), 174-179 (2007).
11. Patard JJ, Pouessel D, Bensalah K, Culine S. Targeted therapy in renal cell carcinoma. World J. Urol. 26(2), 135-140 (2008).
12. Lainakis G, Bamias A. Targeting angiogenesis in renal cell carcinoma. Curr. Cancer Drug Targets 8(5), 349-358 (2008).
13. Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 23(5), 965-972 (2005). (Pubitemid 46202316)
14. Strumberg D, Seeber S. Raf kinase inhibitors in oncology. Onkologie 28(2), 101-107 (2005).
15. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10(1), 25-34 (2009).
16. Dahut WL, Scripture C, Posadas E et al. A Phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin. Cancer Res. 14(1), 209-214 (2008).
17. Gupta-Abramson V, Troxel AB, Nellore A et al. Phase II trial of sorafenib in advanced thyroid cancer. J. Clin. Oncol. 26(29), 4714-4719 (2008).
18. Hauschild A, Agarwala SS, Trefzer U et al. Results of a Phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 27(17), 2823-2830 (2009).
19. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378-390 (2008).
20. Cornu JN, Roupret M, Bensalah K, Oudard S, Patard JJ. Antiangiogenics: new therapeutic standards in metastatic kidney cancer. Prog. Urol. 18(Suppl. 4), S69-S76 (2008).
21. Richter S, Pfister D, Thüer D, Engelmann UH, Heidenreich A. Second-line treatment of progressive metastatic renal cell cancer with temsirolimus following first-line therapy with sunitinib or sorafenib. Onkologie 31(Suppl. 4), V684 (2008).
22. Valcamonico F, Ferrari V, Amoroso V et al. Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma. J. Neurooncol. 91(1), 47-50 (2009).
23. Hill KL, Lipson AC, Sheehan JM. Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma. J. Neurosurg. 111(3), 497-503 (2009).
24. Ranze O, Hofmann E, Distelrath A, Hoeffkes HG. Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib. Onkologie 30(8-9), 450-451 (2007). (Pubitemid 350194942)
25. Bellmunt J, Negrier S, Escudier B, Awada A, Aapro M; SIOG Taskforce. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit. Rev. Oncol. Hematol. 69(1), 64-72 (2009).
26. Bhojani N, Jeldres C, Patard JJ et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur. Urol. 53(5), 917-930 (2008).
27. Ruppin S, Protzel C, Klebingat KJ, Hakenberg OW. Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure. Eur. Urol. 55(4), 986-988 (2008).
28. Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 27(20), 3312-3318 (2009). •• The Treatment Approaches in RCC Global Evaluation Trial (TARGET) trial; Phase III clinical trial comparing sorafenib with placebo as second-line treatment after failure of prior systemic therapy in patients with metastatic RCC.
29. Shepard DR, Rini BR, Garcia J et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J. Clin. Oncol. 26(5123), (2008) (Abstract).
30. Sepulveda J, Maroto P, Andres R et al. Sorafenib as a second-line and sequential therapy for patients with metastatic renal cell carcinoma (mRCC): analysis for safety and activity on sunitinib progressive pts. ASCO Meeting Abstracts 26(15 Suppl.) (2008) (Abstract 16100).
31. Herrmann E, Bierer S, Gerss J, Kopke T, Hertle L, Wulfing C. Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokinerefractory kidney cancer patients. Oncology 74(3-4), 216-222 (2008). •• Prospective comparative data regarding use of sorafenib and sunitinib as second-line treatment of cytokine refractory renal cell cancer patients.
32. Escudier B, Ravaud A, Oudard S et al. Phase III randomized trial of everolimus (RAD001) vs placebo in metastatic renal cell carcinoma. Ann. Oncol. 19, 720 (2008).
33. Drabkin HA, Figlin RA, Stadler WM et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with prior bevacizumab (BEV) treatment. American Society of Clinical Oncology Meeting Abstracts 25(18 Suppl.), (2007) (Abstract 5041).
34. Choueiri TK, Brick AJ, McDermott S et al. Treatment and dosing patterns for angiogenesis inhibitor (AIS) therapies in patients with metastatic renal cell carcinoma (MRCC). Ann. Oncol. 19(Suppl. 8), 593P (2008).
35. Zimmermann K, Schmittel A, Steiner U et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 76(5), 350-354 (2009).
36. Sablin MP, Negrier S, Ravaud A et al. Sequential sorafenib and sunitinib for renal carcinoma. J. Urol. 182, 29-34, (2009).
37. Porta C, Procopio G, Sabbatini R et al. Retrospective analysis of the sequential use of sorafenib and sunitinib in patients with advanced renal cell carcinoma (RCC). Eur. J. Urol. 8 (Suppl. 4), 183 (2009) (Abstract 252). •• Largest retrospective trial investigating sequential use of sorafenib and sunitinib.
38. Beck J, Bajetta E, Escudier B et al. A large open-label non-comparative Phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma. Eur. J. Cancer 5(4 Suppl.), 300 (2007) (Abstract 4506).
39. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon α or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007). (Pubitemid 46849157)
40. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon α-2a for treatment of metastastic renal cell carcinoma: survival and biomarker analysis. Lancet 370, 2103-2111 (2007). (Pubitemid 350296300)
41. Rini BI, Halabi S, Rosenberg JE et al. CALGB 90206: a Phase III trial of bevacizumab plus interferon-α versus interferon-α monotherapy in metastatic renal cell carcinoma. J. Clin. Oncol. 26(33), 5422-5428 (2008).
42. Figlin RA, Hutson TE, Tomczak P et al. Overall survival with sunitinib versus interferon (IFN)-α as first-line treatment of metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 26, 5024 (2008).
43. Kay A, Motzer RJ, Figlin RA et al. Updated data from a Phase III trial of everolimus (RAD001) versus placebo in patients with metastatic renal cell carcinoma. Presented at: European Association of Urology Annual Congress. Stockholm, Sweden, 17-25 March 2009 (Abstract 257).
44. Sternberg CN, Szczylik C, Lee E et al. A randomized, double-blind Phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). Presented at: American Society of Clinical Oncology Annual Meeting. Orlando, FL, USA, 29 May-2 June 2009 (Abstract 5021).